Search results for "phosphonate"

showing 10 items of 372 documents

Staging of osteonecrosis of the jaw requires computed tomography for accurate definition of the extent of bony disease

2014

AbstractManagement of osteonecrosis of the jaw associated with antiresorptive agents is challenging, and outcomes are unpredictable. The severity of disease is the main guide to management, and can help to predict prognosis. Most available staging systems for osteonecrosis, including the widely-used American Association of Oral and Maxillofacial Surgeons (AAOMS) system, classify severity on the basis of clinical and radiographic findings. However, clinical inspection and radiography are limited in their ability to identify the extent of necrotic bone disease compared with computed tomography (CT). We have organised a large multicentre retrospective study (known as MISSION) to investigate th…

AdultMaleCutaneous FistulaSettore MED/50 - Scienze Tecniche Mediche ApplicateDental Fistulastaging system; bisphosphonate; computed tomography; aaoms; osteonecrosis of the jaw; antiresorptive agentsAAOMSAntiresorptive agentSettore MED/29 - Chirurgia MaxillofaccialeAAOMS Antiresorptive agents Bisphosphonate Computed tomography Osteonecrosis of the jaw Staging systemBronj; AAOMS; Antiresorptive agents; Bisphosphonate; Computed tomography; Osteonecrosis of the jaw; Staging systemSettore MED/28 - Malattie OdontostomatologicheMandibular FracturesBronjOsteonecrosis of the jaw; Bisphosphonate; Staging system; AAOMS; Computed tomography; Antiresorptive agentsAlveolar ProcessHumansBisphosphonateMandibular DiseasesComputed tomographyAgedRetrospective StudiesAged 80 and overSuppurationBone Density Conservation AgentsOsteonecrosis of the jawPatient AcuityAntiresorptive agentsCone-Beam Computed TomographyMiddle AgedStaging systemMaxillary DiseasesPhenotypeOtorhinolaryngologyTooth ExtractionBisphosphonate-Associated Osteonecrosis of the JawDrug Therapy CombinationFemaleSurgeryOsteonecrosis of the jaw; Bisphosphonate; Staging system; AAOMS; Computed tomography; Antiresorptive agentsAAOMS; Antiresorptive agents; Bisphosphonate; Computed tomography; Osteonecrosis of the jaw; Staging systemOral SurgeryTomography X-Ray ComputedTomography Spiral ComputedOsteosclerosis
researchProduct

Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: The EPIB 2008 study

2010

To compare the management and the virological and serological efficacy of treatments for chronic hepatitis B (CHB) in HIV positive and negative patients.Two hundred and forty-six HIV positive and 205 HIV negative consecutive patients with past or present CHB, seen in October 2008 in participating departments, were included in a multicenter study. All the data were retrospectively collected from the first visit to October 2008 through a standardized questionnaire.Compared to HIV negative patients, HIV positive patients more often presented positive HBeAg (46.4% vs. 32.8%, p=0.01), HBV genotype A (54.8% vs. 17.1%, p0.0001), co-infection with HCV (12.4% vs. 5.9%, p=0.0002) or HDV (12.6% vs. 2.…

AdultMaleHepatitis B virusmedicine.medical_specialtyOrganophosphonatesHIV InfectionsAntiviral AgentsSerologyHepatitis B AntigensHepatitis B ChronicPharmacotherapyAcquired immunodeficiency syndrome (AIDS)Surveys and QuestionnairesInternal medicinemedicineHumansHepatitis B AntibodiesTenofovirSidaRetrospective StudiesHepatologybiologybusiness.industryAdeninevirus diseasesMiddle AgedHepatitis Bbiology.organism_classificationmedicine.diseaseHBeAgLentivirusImmunologyFemaleFranceViral diseasebusinessJournal of Hepatology
researchProduct

Pathological mandibular fracture after simple molar extraction in a patient with osteogenesis imperfecta treated with alendronate

2009

Osteogenesis imperfecta (OI), is a heterogeneous group of inherited disorders of connective tissue characterized by bone fragility. Patients with this disease frequently suffer fractures, over 80% of the extremities due to the more intensive mechanical load. Fractures of the facial bones occur very infrequently. Several studies have proved that bisphosphonate therapy may be effective in reducing fracture risk in OI patients. We report here an unusual case of pathological mandibular fracture following simple molar extraction in an adult patient with OI type I and oral alendronic acid treatment. Extraction was atraumatical and without bone removal . Fracture was treated by internal fixation b…

AdultMaleMolarmedicine.medical_specialtymedicine.medical_treatmentMandibular fractureConnective tissueDentistryBone healingMandibular FracturesmedicineHumansInternal fixationGeneral DentistryAlendronateDiphosphonatesbusiness.industryAlendronic acidOsteogenesis Imperfectamedicine.disease:CIENCIAS MÉDICAS [UNESCO]MolarSurgeryFractures Spontaneousmedicine.anatomical_structureOtorhinolaryngologyOsteogenesis imperfectaTooth ExtractionUNESCO::CIENCIAS MÉDICASSurgerybusinessComplicationmedicine.drug
researchProduct

Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review

2018

The reporting of osteonecrosis of the jaw (ONJ) related to anticancer agents without known antiresorptive properties (non-antiresorptives), such as antiangiogenics, tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors, immune checkpoint inhibitors, and cytotoxic chemotherapy is increasing. To review characteristics of ONJ in cancer patients receiving non-antiresorptives. A systematic review of the literature between 2009 and 2017 was conducted by the Bone Study Group of MASCC/ISOO. Of 6249 articles reviewed and from personal communication, 42 ONJ cases related to non-antiresorptives were identified. No gender predilection was noted. Median age was 60 years and ONJ stage 2 wa…

AdultMaleOncologyBRAF inhibitormedicine.medical_specialtymTOR inhibitorsImmune checkpoint inhibitorsInhibitors of angiogenesiTyrosine kinase inhibitorBone resorptionImmune checkpoint inhibitorDelayed diagnosisCytotoxic chemotherapyBone resorption03 medical and health sciences0302 clinical medicineProstateInternal medicinemedicineHumans030212 general & internal medicineStage (cooking)AgedBone Density Conservation AgentsDiphosphonatesOsteonecrosis of the jawbusiness.industryOsteonecrosisCancerMiddle AgedCytotoxic chemotherapymedicine.diseasemedicine.anatomical_structureJawOncology030220 oncology & carcinogenesisBisphosphonate-Associated Osteonecrosis of the JawFemaleOsteonecrosis of the jawbusiness
researchProduct

Clinicopathologic features of nasopalatine duct cysts: A retrospective study in two Brazilian oral and maxillofacial pathology referral centers

2021

Background Nasopalatine duct cyst (NDC) is the most common non-odontogenic cyst in the oral cavity. Clinically it is not difficult to suspect these lesions based on clinical and radiographic appearance. However, the histopathological diagnosis may be difficult due to the broad morphological diversity of these lesions. The objective was to analyze the clinicopathological features of NDCs diagnosed in two oral and maxillofacial pathology services in the Brazilian northeast. Material and Methods A retrospective clinicopathologic study was performed. A total of 18,121 clinical records of oral lesions from two oral and maxillofacial pathology services in Brazil were analyzed (2000-2020). All NDC…

AdultMalePathologymedicine.medical_specialtyrecurrenceRadiographyStratified squamous epitheliumAsymptomaticzoledronic acidOral and maxillofacial pathologyNasopalatine duct cystMedicineHumansCystbisphosphonatesplatelet rich plasmaGeneral DentistryReferral and ConsultationUNESCO:CIENCIAS MÉDICASRetrospective StudiesOral Medicine and Pathologybusiness.industryCystsResearchdenosumabRetrospective cohort studymedicine.diseaseNonodontogenic Cystsosteonecrosis of the jawmedicine.anatomical_structurerisk factorOtorhinolaryngologyGiant cellPathology OralSurgeryFemalemedicine.symptombusinessBrazilMedicina Oral, Patología Oral y Cirugía Bucal
researchProduct

Long-Term Efficacy of Tenofovir Monotherapy for Hepatitis B Virus-Monoinfected Patients After Failure of Nucleoside/Nucleotide Analogues

2010

Tenofovir disoproxil fumarate (TDF) has demonstrated high antiviral efficacy in treatment-naive patients with chronic hepatitis B virus (HBV) infection but experience in nucleoside/nucleotide analogue (NA)-experienced patients is limited. In this retrospective multicenter study we therefore assessed the long-term efficacy of TDF monotherapy in patients with prior failure or resistance to different NA treatments. Criteria for inclusion were HBV DNA levels >4.0 log(10) copies/mL at the start and a minimum, period of TDF therapy for at least 6 months. In all, 131 patients (mean age 42 +/- 12 years, 95 male, 65% hepatitis B e antigen [HBeAg]-positive) were eligible. Pretreatment consisted of…

AdultMalemedicine.medical_specialtyHBsAgAdolescentOrganophosphonatesPharmacologyBiologymedicine.disease_causeGastroenterologyCohort StudiesSDG 3 - Good Health and Well-beingInternal medicineDrug Resistance ViralmedicineAdefovirHumansHepatitis B e AntigensTenofovirRetrospective StudiesHepatitis B virusHepatitis B Surface AntigensHepatologyReverse-transcriptase inhibitorAdenineLamivudinevirus diseasesEntecavirHepatitis BMiddle Agedmedicine.diseaseHepatitis BTreatment OutcomeHBeAgLamivudineFemalemedicine.drugHepatology
researchProduct

Current practice of chronic hepatitis B treatment in Southern Italy

2012

Abstract Background Treatment choice for chronic HBV infection is a continuously evolving issue, with a wide range of options. We aimed to evaluate the current practice of HBV therapies in the real world in Southern Italy. Methods A prospective study enrolling over a six month period (February–July 2010) all consecutive HBsAg positive subjects, never previously treated, referred to 16 liver units in two Southern Italy regions (Calabria and Sicily). Results Out of 247 subjects evaluated, 116 (46.9%) had HBV-DNA undetectable or lower than 2000 UI/ml. There were 108 (43.7%) inactive carriers, 103 (41.7%) chronic hepatitis, and 36 (14.6%) liver cirrhosis. Antiviral treatment was planned in 94 (…

AdultMalemedicine.medical_specialtyHBsAgGuanineCirrhosisOrganophosphonatesPyrimidinonesNucleosides analoguesAntiviral AgentsPolyethylene GlycolsYoung AdultHepatitis B ChronicChronic hepatitisInterferonPegylated interferonInternal medicineHBVInternal MedicinemedicineHumansHepatitis B e AntigensPractice Patterns Physicians'TenofovirProspective cohort studyAgedAged 80 and overTelbivudinebusiness.industryAdenineAge FactorsInterferon-alphaNucleosidesMiddle AgedHBV; Interferon; Nucleosides analogues; Nucleotides analoguesNucleotides analoguesmedicine.diseaseRecombinant ProteinsItalyLamivudineCurrent practiceImmunologyInterferonFemalePreviously treatedbusinessThymidinemedicine.drugEuropean Journal of Internal Medicine
researchProduct

Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study.

2014

In hepatitis B e antigen (HBeAg) positive-HIV co-infected patients treated with combined antiretroviral therapy (cART), including tenofovir disoproxil fumarate (TDF), the rate of HBe seroconversion remains low. Whether adding pegylated interferon alfa (PegIFN) could increase the likelihood of HBeAg loss and HBe seroconversion has not been assessed.A 48-week PegIFN therapy was added to HBeAg positive-HIV co-infected patients on TDF and emtricitabine, or lamivudine for at least 6 months. The primary endpoint was HBV sustained response: HBe seroconversion with undetectable HBV DNA levels 24 weeks after completing PegIFN therapy (W72).Fifty-one patients (49 men, median age 46 years, range: 32-6…

AdultMalemedicine.medical_specialtyHBsAgOrganophosphonatesHIV Infectionsmedicine.disease_causeEmtricitabineGastroenterologyAntiviral AgentsDeoxycytidinePolyethylene GlycolsHepatitis B ChronicPegylated interferonInternal medicineAntiretroviral Therapy Highly ActivemedicineEmtricitabineHumansHepatitis B e AntigensSeroconversionTenofovirHepatitis B virusDrug CarriersHepatologybusiness.industryCoinfectionAdeninevirus diseasesLamivudineHIVInterferon-alphaMiddle AgedViral Loaddigestive system diseasesRecombinant ProteinsCD4 Lymphocyte CountTreatment OutcomeHBeAgLamivudineImmunologyFemalebusinessViral loadmedicine.drugJournal of hepatology
researchProduct

Resective surgical approach shows a high performance in the management of advanced cases of bisphosphonate-related osteonecrosis of the jaws: a retro…

2012

Abstract PURPOSE: The aim of this study was to evaluate the results of the surgical treatment of bisphosphonate-related osteonecrosis of the jaw (BRONJ) in a large cohort. MATERIALS AND METHODS: A retrospective cohort multicenter study was designed. Patients were enrolled if they were diagnosed with BRONJ and received operative treatment. Data on demographic, health status, perioperative, and surgical factors were collected retrospectively. The primary outcome variable was a change in BRONJ staging (improvement, worsening, or no change). Interventions were grouped by local debridement and resective surgery. Data were collected for other variables as cofactors. Univariate analysis and logist…

AdultMalemedicine.medical_specialtyMultivariate analysismedicine.medical_treatmentLogistic regressionSettore MED/28 - Malattie OdontostomatologicheHumansMedicinebisphosphonate-related osteonecrosis of the jawsAgedRetrospective StudiesAnalysis of VarianceUnivariate analysisChi-Square Distributionbusiness.industryRetrospective cohort studyPerioperativeMiddle AgedBisphosphonatemedicine.diseaseOsteotomySurgeryTreatment OutcomeDebridementItalyOtorhinolaryngologySurgical Procedures OperativeTooth ExtractionRegression AnalysisBisphosphonate-Associated Osteonecrosis of the JawFemaleSurgeryOral SurgerybusinessOsteonecrosis of the jawChi-squared distribution
researchProduct

Osteonecrosis of the jaws in 194 patients who have undergone intravenous bisphosphonate therapy in Spain.

2014

Background: Osteonecrosis of the jaw (ONJ) is a destructive bone process in patients undergoing bisphosphonate therapy and it is modulated by local and systemic factors. The purpose of this article is to determine the prevalence of ONJ in patients who have undergone intravenous bisphosphonate therapy, and relate the risk factors described to establish a protocol to reduce the risk of developing ONJ. Material and Methods: We performed a retrospective study on 194 patients treated with IV bisphosponates, analyzing clinical and pathological variables. Results: The prevalence of ONJ was 12.9 %. The most remarkable complication was pain, which was reported by 80% of patients. The average age of …

AdultMalemedicine.medical_specialtyOdontologíaOral hygieneRisk FactorsmedicinePrevalenceHumansRisk factorGeneral DentistryPathologicalAgedRetrospective StudiesAged 80 and overBisphosphonate-associated osteonecrosis of the jawOral Medicine and PathologyBone Density Conservation AgentsDiphosphonatesbusiness.industryResearchRetrospective cohort studyMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludSurgeryOtorhinolaryngologySpainUNESCO::CIENCIAS MÉDICASEtiologySurgeryBisphosphonate-Associated Osteonecrosis of the JawFemaleOsteonecrosis of the jawComplicationbusinessMedicina oral, patologia oral y cirugia bucal
researchProduct